−2.06HKD
−848.63 MHKD
192.11 MHKD
380.85 M
About JW (CAYMAN) THERAPEUTICS CO. LTD
Sector
Industry
CEO
Yi Ping Li
Website
Headquarters
Shanghai
Employees (FY)
398
Founded
2017
ISIN
KYG5210T1040
FIGI
BBG00XXS5DK3
JW (Cayman) Therapeutics Co. Ltd. is a clinical stage cell therapy company, which focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. The company was founded by Yi Ping Li on September 6, 2017 and is headquartered in Shanghai, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 2126 is 1.67 HKD — it has decreased by 2.34% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange JW (CAYMAN) THERAPEUTICS CO. LTD stocks are traded under the ticker 2126.
JW (CAYMAN) THERAPEUTICS CO. LTD is going to release the next earnings report on Aug 27, 2024. Keep track of upcoming events with our Earnings Calendar.
2126 stock is 3.01% volatile and has beta coefficient of 0.97. Check out the list of the most volatile stocks — is JW (CAYMAN) THERAPEUTICS CO. LTD there?
One year price forecast for JW (CAYMAN) THERAPEUTICS CO. LTD has a max estimate of 3.56 HKD and a min estimate of 2.20 HKD.
2126 earnings for the last quarter are −1.01 HKD whereas the estimation was −0.92 HKD which accounts for −9.41% surprise. Estimated earnings for the next quarter are −0.89 HKD. See more details about JW (CAYMAN) THERAPEUTICS CO. LTD earnings.
JW (CAYMAN) THERAPEUTICS CO. LTD revenue for the last quarter amounts to 94.82 M HKD despite the estimated figure of 177.35 M HKD. In the next quarter revenue is expected to reach 106.18 M HKD.
Yes, you can track JW (CAYMAN) THERAPEUTICS CO. LTD financials in yearly and quarterly reports right on TradingView.
2126 stock has fallen by 5.65% compared to the previous week, the month change is a 16.50% fall, over the last year JW (CAYMAN) THERAPEUTICS CO. LTD has showed a 52.29% decrease.
2126 net income for the last quarter is −418.72 M HKD, while the quarter before that showed −430.23 M HKD of net income which accounts for 2.68% change. Track more JW (CAYMAN) THERAPEUTICS CO. LTD financial stats to get the full picture.
Today JW (CAYMAN) THERAPEUTICS CO. LTD has the market capitalization of 683.95 M, it has increased by 0.80% over the last week.
No, 2126 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 2126 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JW (CAYMAN) THERAPEUTICS CO. LTD stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 398.00 employees. See our rating of the largest employees — is JW (CAYMAN) THERAPEUTICS CO. LTD on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So JW (CAYMAN) THERAPEUTICS CO. LTD technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating JW (CAYMAN) THERAPEUTICS CO. LTD stock shows the sell signal. See more of JW (CAYMAN) THERAPEUTICS CO. LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on JW (CAYMAN) THERAPEUTICS CO. LTD future price: according to them, 2126 price has a max estimate of 3.56 HKD and a min estimate of 2.20 HKD. Read a more detailed JW (CAYMAN) THERAPEUTICS CO. LTD forecast: see what analysts think of JW (CAYMAN) THERAPEUTICS CO. LTD and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. JW (CAYMAN) THERAPEUTICS CO. LTD EBITDA is −532.97 M HKD, and current EBITDA margin is −276.69%. See more stats in JW (CAYMAN) THERAPEUTICS CO. LTD financial statements.